Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 150 AML: ivosidenib or enasidenib plus intensive chemotherapy in newly diagnosed IDH-mutated AML/MDS-EB2
2022-502832-37-00Phase 3Authorised
- Sponsor
- HOVON
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of ivosidenib and enasidenib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (4 arms), sponsored by HOVON. Primary endpoints: Event-free survival and Event-free survival censoring rule. Planned start Nov 2024; status: authorised.
02
Drugs
ivosidenibenasidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2022-502832-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502832-37-00.